Cargando…

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics

Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting ≥6 months comparing SGAs with FGAs in schizophrenia. Primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishimoto, Taishiro, Agarwal, Vishesh, Kishi, Taro, Leucht, Stefan, Kane, John M., Correll, Christoph U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320691/ https://www.ncbi.nlm.nih.gov/pubmed/22124274 http://dx.doi.org/10.1038/mp.2011.143

Ejemplares similares

Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2022)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
por: Leucht, Stefan, et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics
por: Skonieczna-Żydecka, Karolina, et al.
Publicado: (2020)

Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis
por: Kishimoto, Taishiro, et al.
Publicado: (2023)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS
por: Rubio, Jose, et al.
Publicado: (2018)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
por: Solmi, Marco, et al.
Publicado: (2017)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis
por: Ansell, B. R. E., et al.
Publicado: (2015)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Blood lactate levels in patients receiving first- or second- generation antipsychotics
por: Glavina, Trpimir, et al.
Publicado: (2011)

Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
por: Miller, Brian J., et al.
Publicado: (2011)

T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

First-generation antipsychotics: not gone but forgotten
por: Dibben, Claire R. M., et al.
Publicado: (2016)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives
por: Correll, Christoph U., et al.
Publicado: (2011)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
por: Mahmoud, Ahmed, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia
por: Washida, Kenji, et al.
Publicado: (2013)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3hkikfhf3ldkk4s92f93l75g27